NASDAQ: EDIT · Life Sciences · 5 alerts · CIK 1650664
Share price
$1.87Close, Nov 16
Market cap
$289M
Shares outstanding
154.34MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Editas Medicine, Inc. filings on SEC EDGAR ↗
Editas Medicine CEO Gilmore Neil O'Neill Sells $51.1K of Stock
Gilmore Neil O'Neill, CEO, sold 21,164 shares of Editas Medicine, Inc. at $2.42 a share, worth $51.1K in total on Nov 11, 2026. Shares held after the trade: 265,592 (-7.4%).
Editas Medicine EVP, CSO Linda Burkly Sells $18.9K of Stock
Linda Burkly, EVP, CSO, sold 7,814 shares of Editas Medicine, Inc. at $2.42 a share, worth $18.9K in total on Nov 11, 2026. Shares held after the trade: 70,379 (-10.0%).
Editas Medicine reported a net loss of $23.4 million for the third quarter of 2026, a significant improvement from the $154.4 million loss in the prior year period which was impacted by restructuring charges. The company strengthened its balance sheet through a $116.9 million common stock and warrant financing, ending the period with $190.2 million in cash, cash equivalents, and marketable securities.
Editas Medicine reported Q3 2026 financial results, highlighting a cash runway extending into the second half of 2028. The company received regulatory approval to initiate its Phase 1/2 Strive study for EDIT-401 in Australia and triggered a milestone payment from Bristol Myers Squibb following the acceptance of a second IND/CTA for their CAR T collaboration.
Term
Q3 2026
“We are incredibly excited by the progress we made in the third quarter as we advanced EDIT-401, our potentially best-in-class in vivo gene editing medicine for hyperlipidemia, towards the clinic.”
Gilmore O’Neill, M.B., M.M.Sc., President and Chief Executive Officer
Editas Medicine received approval to initiate its Phase 1/2 Strive clinical trial for EDIT-401 in Australia, targeting patients with heterozygous familial hypercholesterolemia. The company expects to begin patient dosing in 2026 and report initial safety and tolerability data in the first quarter of 2027. Additionally, the company will present new preclinical data demonstrating durable LDL-C reduction at the AHA Scientific Sessions in November 2026.